{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:5482"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:5482","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Identification and evaluation of biomarkers for the detection of bladder cancer","abstract":"Urinary Bladder Cancer (UBC) is the 5th most common cancer in the West (Cancer Research UK 2014). Continuous efforts have been made to develop non-invasive urine-based biomarkers with high sensitivity and specificity that would improve patients’ quality of life, costs and lower the number of cystoscopies (Bryan et al. 2010). This can then be utilized as part of a multi-biomarker panel to develop a urine test for UBC diagnosis as a single marker is unable to replace current diagnostic invasive tools (Brentnall et al. 2012). PMA increases secretion and shedding of proteins and has an effect on the cell phenotype. Despite Marimastat inhibits shedding of EpCAM, it does not have an effect on cell phenotype. Urinary MMP1 is not a useful neither prognostic nor diagnostic biomarker of UBC. Elevated MMP-1 levels are only apparent in high stages and grade.","abstract_html":"Urinary Bladder Cancer (UBC) is the 5th most common cancer in the West (Cancer Research UK 2014). Continuous efforts have been made to develop non-invasive urine-based biomarkers with high sensitivity and specificity that would improve patients’ quality of life, costs and lower the number of cystoscopies (Bryan et al. 2010). This can then be utilized as part of a multi-biomarker panel to develop a urine test for UBC diagnosis as a single marker is unable to replace current diagnostic invasive tools (Brentnall et al. 2012). PMA increases secretion and shedding of proteins and has an effect on the cell phenotype. Despite Marimastat inhibits shedding of EpCAM, it does not have an effect on cell phenotype. Urinary MMP1 is not a useful neither prognostic nor diagnostic biomarker of UBC. Elevated MMP-1 levels are only apparent in high stages and grade.","abstract_has_math":false,"creators":["Abbas, Hafsa"],"institution":"University of Birmingham","degree_name":"m_rs","degree_level":"m_rs","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-12","date_published":"2014-12","updated_at":"2026-11-19T09:28:23Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/5482/1/Abbas14MRes.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A5482","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Abbas, Hafsa"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2014-12"]},{"key":"dc:date.issued","label":"Date","values":["2014-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer Studies"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/5482/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_rs"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_rs"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/5482/1/Abbas14MRes.pdf","http://etheses.bham.ac.uk//id/eprint/5482/2/Decl_IS_Abbas14MRes.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Urinary Bladder Cancer (UBC) is the 5th most common cancer in the West (Cancer Research UK 2014). Continuous efforts have been made to develop non-invasive urine-based biomarkers with high sensitivity and specificity that would improve patients’ quality of life, costs and lower the number of cystoscopies (Bryan et al. 2010). This can then be utilized as part of a multi-biomarker panel to develop a urine test for UBC diagnosis as a single marker is unable to replace current diagnostic invasive tools (Brentnall et al. 2012). PMA increases secretion and shedding of proteins and has an effect on the cell phenotype. Despite Marimastat inhibits shedding of EpCAM, it does not have an effect on cell phenotype. Urinary MMP1 is not a useful neither prognostic nor diagnostic biomarker of UBC. Elevated MMP-1 levels are only apparent in high stages and grade."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Identification and evaluation of biomarkers for the detection of bladder cancer"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Abbas, Hafsa"],"dc:date":["2014-12"],"dc:date.issued":["2014-12"],"dc:description.abstract":["Urinary Bladder Cancer (UBC) is the 5th most common cancer in the West (Cancer Research UK 2014). Continuous efforts have been made to develop non-invasive urine-based biomarkers with high sensitivity and specificity that would improve patients’ quality of life, costs and lower the number of cystoscopies (Bryan et al. 2010). This can then be utilized as part of a multi-biomarker panel to develop a urine test for UBC diagnosis as a single marker is unable to replace current diagnostic invasive tools (Brentnall et al. 2012). PMA increases secretion and shedding of proteins and has an effect on the cell phenotype. Despite Marimastat inhibits shedding of EpCAM, it does not have an effect on cell phenotype. Urinary MMP1 is not a useful neither prognostic nor diagnostic biomarker of UBC. Elevated MMP-1 levels are only apparent in high stages and grade."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/5482/1/Abbas14MRes.pdf","http://etheses.bham.ac.uk//id/eprint/5482/2/Decl_IS_Abbas14MRes.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer Studies"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/5482/"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Identification and evaluation of biomarkers for the detection of bladder cancer"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_rs"],"dc:type.qualificationname":["m_rs"]},"updated_at":"2026-11-19T09:28:23Z"}